Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Am J Pharm Educ ; 87(5): 100011, 2023 05.
Article in English | MEDLINE | ID: covidwho-2310756

ABSTRACT

Vulnerable populations are those who experience disparity at a disproportionate rate. For this article, specific vulnerable populations of interest include people who experience intellectual or developmental disorders, mental illness, or substance misuse. Vulnerable populations are some of the most stigmatized populations in our society. Research shows that vulnerable populations receive less empathic care than general health care populations, resulting in reduced quality of care and disparities in health outcomes. Empathy, a necessary health care competency, is associated with improved patient outcomes, enhanced job satisfaction, and increased retention and resilience across health care professions. However, there is no current standard for how empathy is taught, assessed, or sustained. Even when empathy education is implemented in healthcare professions curricula, research has demonstrated that it appears to erode with experience and time. In addition, the COVID-19 pandemic has exacerbated inequities in health care systems, with consequences for both patients and providers. There is an urgent need to develop efficacious training in empathy across health care professions to foster and sustain a robust workforce and improve health care experiences and outcomes.


Subject(s)
COVID-19 , Education, Pharmacy , Humans , Empathy , Pandemics , COVID-19/epidemiology , Delivery of Health Care
2.
Innov Pharm ; 12(4)2021.
Article in English | MEDLINE | ID: covidwho-2026325

ABSTRACT

COVID-19 spurred rapid expansion of pharmacy-based point-of-care testing (POCT). This growth was aided, in part, by federal guidance that removed state-level regulatory uncertainty surrounding the ability of pharmacists to administer, interpret, and act on the results of tests. Surveys suggest there is considerable confusion about the legality of these services by state regulators. To ensure the sustainability of POCT services over time, states should consider adopting a standard of care approach to regulation, allowing a flexible framework for practice innovation and expansion over time.

3.
J Pharm Pract ; : 8971900221087129, 2022 Apr 12.
Article in English | MEDLINE | ID: covidwho-1785024

ABSTRACT

BACKGROUND: In April 2020, pharmacists were added as medical providers under Idaho Medicaid in response to recent scope expansion for pharmacists and to increase beneficiaries' access to coronavirus disease 2019 (COVID-19) testing and services. The COVID-19 pandemic prompted expedited Medicaid enrollment for pharmacists but did not address coverage of medical services provided to privately insured individuals for pharmacy-based testing services. OBJECTIVE: This study aimed to describe processes used by independently owned, community-based pharmacies in Idaho to credential with private insurers and report outcomes. METHODS: Relevant information and forms required to credential with the four major payers in the state of Idaho were collected. Packets were obtained via medical insurers' websites and by direct contact. Questions that arose from community pharmacists during the submission process were collected and answered on a shared spreadsheet, and insurance representatives were contacted directly to resolve questions. RESULTS: Eight out of 13 participating pharmacies submitted an average of three credentialing packets for their facilities. Thirty-five pharmacists also submitted an average of four credentialing packets for themselves. As of mid-May 2021, nearly 20 weeks after submission, only 67 out of 129 pharmacists had received word regarding the status of their applications. Less than half of all pharmacist applications were approved (after their first attempt). CONCLUSION: Efforts to support the education of both pharmacists and medical insurers may streamline the credentialing processes in the future.

4.
American Journal of Pharmaceutical Education ; 85(10):1143-1149, 2021.
Article in English | ProQuest Central | ID: covidwho-1627979

ABSTRACT

[...]of the ongoing pandemic, members met virtually throughout the 2020-2021 academic year to begin developing a framework and plan to address each of the 4 charges. CHARGE 2 SUBGROUP Background As the COVID-19 pandemic unfolded in the United States (US) in 2020, unprecedented federal expansion of scope of practice ("Scope") for pharmacists has been implemented by the US Department of Health and Human Services (DHHS) via the PREP Act. While the federal government has covered the cost of the vaccines and has provided supplemental funding to support access during the COVID-19 pandemic, payment for advanced patient care services provided by pharmacists in the future will be necessary for these services to be sustainable. CPAs * Continue to support the model that allows all licensed pharmacists with appropriate training to participate in CPAs, and does not restrict participation to subset of licensed pharmacists * Continue supporting the population model of CPAs which increases patient access and does not add undue regulatory burden to the process * Discourage use of patient-specific CPAs in meeting public health needs o Patient-specific CPAs are ineffective during a public health emergency * Encourage state boards of pharmacy to outline

5.
J Am Pharm Assoc (2003) ; 62(1): 253-259, 2022.
Article in English | MEDLINE | ID: covidwho-1356282

ABSTRACT

BACKGROUND: The coronavirus disease Rapid Antigen Testing Expansion Program (Program) employed a drive-thru model to maximize pharmacy staff and the public's safety. OBJECTIVES: To quickly design, implement, and disseminate a pharmacy-based point-of-care testing program during a public health crisis. PRACTICE DESCRIPTION: Community pharmacies in Idaho were engaged in the state's public health efforts to boost severe acute respiratory syndrome coronavirus 2 testing statewide. Geographic location was a major recruitment factor. Two recruitment periods were held to extend the Program's reach into more remote underserved communities. PRACTICE INNOVATION: Program and pharmacy staff developed workflows and materials in an iterative process. Pharmacies received testing supplies. Program staff created e-Care plans for documentation and reimbursement and designed a Web portal for state reporting of positive rapid antigen test results. EVALUATION METHODS: Testing data (pharmacy location, patient insurance status, test type and results, number of submitted Medicaid claims) were captured in an online form. RESULTS: From September to December 2020, 13 pharmacies opted into a drive-thru, rapid antigen point-of-care testing and nasal swab for offsite testing program. A total of 2425 tests were performed. Approximately 29.4% of point-of-care tests were positive, and 70.6% required backup polymerase chain reaction confirmatory analysis. Patient insurance breakdown was 72.1% private, 8% Medicare, 11.4% Medicaid, and 8.5% uninsured. On average, pharmacies tested patients an average of 2.3 hours/day and 2.6 days/week. As a group, they provided 77.5 hours of testing per week statewide. Program pharmacies accounted for an average of 5.1% of testing across the entire state at the end of December 2020. CONCLUSION: Independent community-based pharmacies should be considered as partners in public health initiatives.


Subject(s)
COVID-19 , Community Pharmacy Services , Pharmacies , Aged , COVID-19 Testing , Humans , Medicare , SARS-CoV-2 , United States , Workflow
6.
Am J Pharm Educ ; 85(10): 8715, 2021 11.
Article in English | MEDLINE | ID: covidwho-1323405

ABSTRACT

EXECUTIVE SUMMARY For the American Association of Colleges of Pharmacy (AACP), strategic engagement is critical to the success of colleges and schools of pharmacy in expanding pharmacy and public health practice, meeting programmatic needs, and fulfilling institutional missions. The 2020-2021 Strategic Engagement Standing Committee was charged with identifying effective strategies to leverage the temporary expansion of pharmacist practice capabilities granted during the COVID-19 pandemic for sustained practice. The group was also tasked with looking at ways to partner with the Association of American Medical Colleges (AAMC), our medicine counterparts to develop a plan for collaborating with them to advance interprofessional practice. In this unique year, all standing committees were charged with reading all the reports last year to put President Lin's charges into perspective with the hopes of carrying over the overall theme and work of the previous years committee. Overall, throughout the COVID-19 pandemic, there have been several expansions on the scope of practice for pharmacists and vary by state. We hope to draw out some of those expansions to see how we can build upon efforts to make those permanent.


Subject(s)
COVID-19 , Education, Pharmacy , Advisory Committees , Humans , Pandemics , Pharmacists , SARS-CoV-2 , Schools, Pharmacy , Societies, Pharmaceutical , United States
7.
Expert Rev Mol Diagn ; 21(8): 751-755, 2021 08.
Article in English | MEDLINE | ID: covidwho-1269466

ABSTRACT

Introduction: Pharmacy-based point-of-care testing has long had the potential to improve patient access to timely care, but adoption has been slowed by financial and regulatory barriers. The COVID-19 pandemic reduced or temporarily eliminated many of the barriers to pharmacy-based testing. This review examines how the changes brought on by may impact pharmacy-based testing after the pandemic.Areas covered: This review searched peer-reviewed, lay, and regulatory literature to explore the implementation of pharmacy-based COVID-19 testing. This includes a review of regulatory and financial changes that removed barriers to testing. Additionally, it reviews the literature related to the growth of pharmacy-based testing.Expert opinion: It is clear that the COVID-19 pandemic created an awareness and opportunity for pharmacy-based point-of-care testing. The changes made in response to the pandemic have the potential to increase the role of pharmacy-based testing, but additional regulatory changes and wider pharmacy adoption are still needed to maximize the value of such services.


Subject(s)
COVID-19 Testing , Community Pharmacy Services , Point-of-Care Testing/organization & administration , COVID-19/epidemiology , Community Pharmacy Services/economics , Community Pharmacy Services/legislation & jurisprudence , Humans , Point-of-Care Testing/economics , Point-of-Care Testing/legislation & jurisprudence , Reimbursement Mechanisms
8.
Pediatr Dermatol ; 38(3): 629-631, 2021 May.
Article in English | MEDLINE | ID: covidwho-1105364

ABSTRACT

Since the onset of the COVID-19 pandemic, the growing body of literature has largely focused on the adult population. Reported symptoms among children appear to be consistent with those in adults, including fever, respiratory symptoms, and gastrointestinal symptoms, though children may experience an overall milder disease course. Viral exanthems with possible association to COVID-19 have been reported in pediatric patients. We describe a 10-month-old boy with Gianotti-Crosti syndrome in the setting of recent SARS-CoV-2 RT-PCR positive testing to increase physician awareness and add to the collection of cutaneous manifestations of COVID-19.


Subject(s)
Acrodermatitis , COVID-19 , Exanthema , Acrodermatitis/diagnosis , Acrodermatitis/etiology , Child , Exanthema/diagnosis , Exanthema/etiology , Humans , Infant , Male , Pandemics , SARS-CoV-2
9.
Res Social Adm Pharm ; 17(9): 1574-1578, 2021 09.
Article in English | MEDLINE | ID: covidwho-989187

ABSTRACT

BACKGROUND: The Clinical Laboratory Improvement Amendments of 1988 (CLIA) enabled greater access to low-risk tests by allowing their use in facilities with a Certificate of Waiver in the U.S. Recently, the 2019 novel coronavirus (COVID-19) pandemic has shined a spotlight on CLIA-waived diagnostic testing. To meet this increased patient demand for diagnostic testing, the U.S. Department of Health and Human Services (HHS) authorized licensed pharmacists to order and administer FDA authorized COVID-19 tests. OBJECTIVE: This study aims to update the previous national benching report and examine both the number of pharmacies in the United States with CLIA Certificates of Waiver before and after the SARS-CoV-2 pandemic and the state-by-state differences in the percentage of pharmacies with CLIA Certificates of Waiver. METHODS: Data were collected from the U.S. Centers for Disease Control and Prevention CLIA Laboratory Search website May 3rd, 2015, August 4th, 2019 and November 26th, 2020. The website allows for exportation of demographic data on all CLIA-waived facilities by state. RESULTS: Pharmacies exhibited the largest growth both in number (4865 new locations) and by percent (45%) of CLIA-waived facilities between 2015 and 2020. The total number of pharmacies with a CLIA-waiver grew from 10,626 (17.94%) locations in 2015 to 12,157 (21.43%) locations in 2019, to 15,671 (27.63%) locations in 2020. States demonstrated considerable variability in the percentage of pharmacies with a CLIA-waiver, with a range of 2.92%-56.52%. CONCLUSIONS: Pharmacies have become an increasingly important location for patients to access CLIA-waived tests in the United States, now serving as the second largest provider of CLIA-waived tests by the total number of locations. Most of this growth occurred between 2019 and 2020 due to the COVID-19 pandemic, and concentrated efforts will be necessary to sustain this momentum.


Subject(s)
COVID-19 , Pharmacies , Humans , Pandemics , Prevalence , SARS-CoV-2 , United States
SELECTION OF CITATIONS
SEARCH DETAIL